- Posted July 24, 2014 by
Melville, New York
Morcellation Lawsuits Start To Be Filed Due To Development of Leiomyosarcoma In Patients Who Have Morcellation During Surgery
Morcellators, electronic devices used to remove tissue during hysterectomies and other gynecological surgeries, have been tied to the spread of a rare, but aggressive, uterine cancer called leiomyosarcoma. Since 2013, a number of morcellator cancer lawsuits have been filed against Ethicon Inc., Blue Endo, Lina Medical, and other medical device manufacturers that market these instruments. Plaintiffs in these lawsuits claim that they were never warned that morcellation has the potential to “seed” undiagnosed leiomyosarcoma present in uterine fibroids, leading to the spread of the cancer.
It is estimated that morcellation is used in some 80,000 of the 600,000 hysterectomies performed annually, most for the treatment of benign tumors called fibroids. On rare occasions, cancer cells from undiagnosed leiomyosarcoma can hide within these fibroids. Leiomyosarcoma is a cancer of smooth muscle cells that can occur in the uterus, stomach and intestines, walls of all blood vessels, and skin. While this cancer is very rare, there is no reliable test to diagnose potential malignancy in fibroids before a woman undergoes morcellation. If the cancer is present during morcellation, the cells can be spread throughout the body, quickly changing a stage 1 cancer into stage 4.